Prostate Cancer - Results from #19760

Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy - Abstract October 17, 2014

Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy - Abstract October 17, 2014

Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: Results from a retrospective two-centre trial - Abstract October 17, 2014

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: Clinical controversies - Abstract October 17, 2014

Robot-assisted versus other types of radical prostatectomy: Population-based safety and cost comparison in Japan, 2012-2013 - Abstract October 17, 2014

A comparison of web-based versus print-based decision aids for prostate cancer screening: Participants' evaluation and utilization - Abstract October 17, 2014

Early closure of phase II prospective study on acute and late tolerance of hypofractionated radiotherapy in low-risk prostate cancer patients - Abstract October 17, 2014

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): Study protocol for a randomized phase II trial - Abstract October 15, 2014

Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer - Abstract October 15, 2014

Robot-assisted prostatectomy in obese patients: How influential is obesity on operative outcomes? - Abstract October 15, 2014

Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer - Abstract October 15, 2014

Medical treatment for biochemical relapse after radiotherapy - Abstract October 15, 2014

Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer - Abstract October 15, 2014

An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study - Abstract October 15, 2014

Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer - Abstract October 15, 2014

Transrectal ultrasound guidance for early transurethral recatheterization after radical prostatectomy - Abstract October 15, 2014

Therapeutic vaccines as a promising treatment modality against prostate cancer: Rationale and recent advances - Abstract October 15, 2014

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR) - Abstract October 15, 2014

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: Final analysis of a multicentre, open-label, early-access protocol trial - Abstract October 14, 2014

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer - Abstract October 14, 2014

Page 989 of 1447